Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-κB and reduces the malignant potential of prostate cancer cells in vitro and in vivo

Clinical Cancer Research

Volumn 14, Issue 17, 2008, Pages 5376-5384

  Golovine, Konstantin ^a   Makhov, Peter ^a   Uzzo, Robert G ^a   Shaw, Tavis ^a   Kunkle, David ^a   Kolenko, Vladimir M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN ZIP1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ZINC; ZINC TRANSPORTER; CATION TRANSPORT PROTEIN; SLC39A1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL DEATH; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; CANCER INVASION; CANCER TRANSPLANTATION; DRUG ANTAGONISM; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 53049083485     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0455     Document Type: Article

References (46)

1. Costello LC, Franklin RB. Novel role of zincin the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998;35:285-96.
2. Costello LC, Franklin RB. The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000;59:269-82.
3. Franklin RB, Feng P, Milon B, et al. hZIP1 zincuptake transporter down regulation and zincdepletion in prostate cancer. Mol Cancer 2005;4:32.
4. Ogunlewe JO, Osegbe DN. Zinc and cadmium concentrations in indigenous blacks with normal, hyper-trophic, and malignant prostate. Cancer 1989;63:1388-92.
5. Zaichick V, Sviridova TV, Zaichick SV. Zinc in the human prostate gland: normal, hyperplasticand cancerous. Int Urol Nephrol 1997;29:565-74.
6. Feng P, Li TL, Guan ZX, Franklin RB, Costello LC. Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 2002;52:311-8.
7. Feng P, Liang JY, Li TL, et al. Zinc induces mitochondria apoptogenesis in prostate cells. Mol Urol 2000;4:31-6.
8. 2+ axis may play a role in human prostate cancer cell invasion. Cancer Lett 2004;207:79-87.
9. Ishii K, Usui S, Sugimura Y,et al. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001;92:49-54.
10. Feustel A, Wennrich R, Schmidt B. Serum-Zn-levels in prostatic cancer. Urol Res1989;17:41-2.
11. McMahon RJ, Cousins RJ. Regulation of the zinc transporter ZnT-1 by dietary zinc. Proc Natl Acad Sci U S A1998;95:4841-6.
12. Gaither LA, Eide DJ. The human ZIP1 transporter mediates zinc uptake in human K562 erythroleukemia cells. J Biol Chem 2001;276:22258-64.
13. Gaither LA, Eide DJ. Functional expression of the human hZIP2 zinc transporter. J Biol Chem 2000;275:5560-4.
14. Costello LC, Liu Y, Zou J, Franklin RB. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J Biol Chem 1999;274:17499-504.
15. Kambe T, Yamaguchi-Iwai Y, Sasaki R, Nagao M. Overview of mammalian zinc transporters. Cell Mol Life Sci 2004;61:49-68.
16. Eide DJ.TheSLC39 family of metal ion transporters. Pflugers Arch 2004;447:796-800.
17. Rishi I, Baidouri H, Abbasi JA, et al.Prostate cancer in African American men is associated with downre-gulation of zinc transporters. Appl Immunohistochem Mol Morphol 2003;11:253-60.
18. Franklin RB, Ma J, Zou J, et al. Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. J Inorg Biochem 2003;96:435-42.
19. Huang L, Kirschke CP, Zhang Y. Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression. Cancer Cell Int 2006;6:10.
20. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 2006;5:17.
21. Uzzo RG, Crispen P, GolovineK, Makhov P, Horwitz E, KolenkoVM. Diverse effects of zinc on NF-κBand AP-1transcription factors: implications for prostate cancer progression. Carcinogenesis 2006;27:1980-90.
22. Uzzo RG, Leavis P, Hatch W, et al. Zinc inhibits nuclear factor-κB activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res 2002;8:3579-83.
23. Hsu TC, Nair R, Tulsian P, et al. Transformation non- responsive cells owe their resistance to lack of p65/ nuclear factor-κB activation. Cancer Res 2001;61:4160-8.
24. Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 2007;446:690-4.
25. Lashinger LM, Zhu K,WilliamsSA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005;65:4902-8.
26. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-κB. Oncogene 2006;25:6800-16.
27. Kolenko V, BloomT, Rayman P, Bukowski R, Hsi E, Finke J. Inhibition of NF-κB activity in human T lymphocytes induces caspase-dependent apoptosis without detectable activation of caspase-1 and -3. J Immunol 1999;163:590-8.
28. Lu S, Lee J, Revelo M, Wang X, Lu S, Dong Z. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res 2007;13:5692-702.
29. Wu L, Pu Z, Feng J, Li G, Zheng Z, Shen W. The ubiquitin-proteasome pathway and enhanced activity of NF-nB in gastric carcinoma. J Surg Oncol 2007;97:439-44.
30. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-κBactivityinhumanpros-tate cancer cells is associated with suppression of an-giogenesis, invasion, and metastasis. Oncogene 2001;20:4188-97.
31. Sweeney C, Li L, Shanmugam R, et al. Nuclear fac-tor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004;10:5501-7.
32. Henry J. Clinical diagnosis and management by laboratory methods. 19th ed. Philadelphia (PA): WB Saunders Co.; 1996.
33. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
34. AalinkeelR,NairMP,SufrinG,etal.Geneexpression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004;64: 5311-21.
35. Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998;51:161-7.
36. Tozawa K, Sakurada S, Kohri K, Okamoto T. Effects of anti-nuclear factor κB reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res 1995;55:4162-7.
37. Farina AR, Cappabianca L, MackayAR, et al. Transcriptional regulation of intercellular adhesion molecule 1 by phorbol ester in human neuroblastoma cell line SK-N-SH involves jun- and fos-containing activator protein 1 site binding complex(es). Cell Growth Differ 1997;8:789-800.
38. Gho YS, Kim PN, Li HC, Elkin M, Kleinman HK. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res 2001; 61:4253-7.
39. Coffey RN, Watson RW, O'Neill AJ, McEleny K, Fitzpatrick JM. Androgen-mediated resistance to apoptosis. Prostate 2002;53:300-9.
40. Franklin RB, Costello LC. Zincas an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys 2007;463:211-7.
41. Suh J, Payvandi F, Edelstein LC, et al. Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate 2002;52:183-200.
42. TuY, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998;58:256-62.
43. Papadopoulos K. Targeting the Bcl-2 family in cancer therapy. Semin Oncol 2006;33:449-56.
44. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006;13:179-88.
45. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999;274: 5053-60.
46. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem Soc Symp 1999;66:1-15.